Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%–2% of the population over the age of 65. As the population ages, it is anticipated that the burden on society will significantly escalate. Although symptom reduction by currently available pharmacological and/or surgical treatments improves the quality of life of many PD patients, there are no treatments that can slow down, halt, or reverse disease progression. Because the loss of a specific cell type, midbrain dopamine neurons in the substantia nigra, is the main cause of motor dysfunction in PD, it is considered a promising target for cell replacement therapy. Indeed, numerous preclinical and clinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells remains fraught with controversy due to fundamental ethical, practical, and clinical limitations. Groundbreaking work on human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, coupled with extensive basic research in the stem cell field offers promising potential for hPSC-based cell replacement to become a realistic treatment regimen for PD once several major issues can be successfully addressed. In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for PD.
Citations
Citations to this article as recorded by
Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes Irfan Ali, Mohammad Adil, Mohammad Imran, Saba Asif Qureshi, Saima Qureshi, Nazeer Hasan, Farhan Jalees Ahmad Drug Delivery and Translational Research.2025;[Epub] CrossRef
Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment Vick Key Tew, Muttiah Barathan, Fazlina Nordin, Jia Xian Law, Min Hwei Ng Pharmaceutics.2025; 17(3): 284. CrossRef
Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson’s disease: Insights from non-human primate studies Marina E. Emborg, Jeanette M. Metzger, Kevin D’Amour, Julia C. Colwell, Lindsey C. Neumann, Ai Zhang, Howard J. Federoff Brain Research Bulletin.2025; 224: 111297. CrossRef
Stem Cell-Based Approaches in Parkinson's Disease Research Min Seong Kim, Subeen Yoon, Jiwoo Choi, Yong Jun Kim, Gabsang Lee International Journal of Stem Cells.2025; 18(1): 21. CrossRef
Central and Peripheral Immunity Responses in Parkinson’s Disease: An Overview and Update Ghaidaa Ebrahim, Hunter Hutchinson, Melanie Gonzalez, Abeer Dagra Neuroglia.2025; 6(2): 17. CrossRef
RNA-based controllers for engineering gene and cell therapies Kei Takahashi, Kate E Galloway Current Opinion in Biotechnology.2024; 85: 103026. CrossRef
Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells Min Seong Kim, Hyesoo Kim, Gabsang Lee Advanced Healthcare Materials.2024;[Epub] CrossRef
A recent update on drugs and alternative approaches for parkinsonism Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty Neuropeptides.2024; 104: 102415. CrossRef
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders Jessica Cohen, Annette Mathew, Kirk D. Dourvetakis, Estella Sanchez-Guerrero, Rajendra P. Pangeni, Narasimman Gurusamy, Kristina K. Aenlle, Geeta Ravindran, Assma Twahir, Dylan Isler, Sara Rukmini Sosa-Garcia, Axel Llizo, Alison C. Bested, Theoharis C. Th Cells.2024; 13(6): 511. CrossRef
Continuous immunosuppression is required for suppressing immune responses to xenografts in non-human primate brains Su Feng, Ting Zhang, Zhengxiao He, Wenchang Zhang, Yingying Chen, Chunmei Yue, Naihe Jing Cell Regeneration.2024;[Epub] CrossRef
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets Alhamdu Adamu, Shuo Li, Fankai Gao, Guofang Xue Frontiers in Aging Neuroscience.2024;[Epub] CrossRef
Past, present, and future of cell replacement therapy for parkinson’s disease: a novel emphasis on host immune responses Tae-Yoon Park, Jeha Jeon, Young Cha, Kwang-Soo Kim Cell Research.2024; 34(7): 479. CrossRef
Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms Mary Dayne Sia Tai, Gloria Gamiz-Arco, Aurora Martinez Biochemical Society Transactions.2024; 52(3): 1275. CrossRef
Experimental models of Parkinson's disease: Challenges and Opportunities Roshan Lal, Aditi singh, Shivam watts, Kanwaljit Chopra European Journal of Pharmacology.2024; 980: 176819. CrossRef
The prospective role of mesenchymal stem cells in Parkinson's disease Pratima Tambe, Vaishali Undale, Avinash Sanap, Ramesh Bhonde, Nishant Mante Parkinsonism & Related Disorders.2024; 127: 107087. CrossRef
Current Landscape of iPSC Haplobanks Rubén Escribá, Meral Beksac, Annelise Bennaceur-Griscelli, Joel C. Glover, Satu Koskela, Helen Latsoudis, Sergi Querol, Belén Alvarez-Palomo Stem Cell Reviews and Reports.2024; 20(8): 2155. CrossRef
Circuit integration by transplanted human neurons Qiang Yuan, Su-Chun Zhang Current Opinion in Genetics & Development.2024; 89: 102225. CrossRef
The Abnormal Proliferation of Midbrain Dopamine Cells From Human Pluripotent Stem Cells Is Induced by Exposure to the Tumor Microenvironment Jun Xue, Dongyan Wu, Yuting Bao, Yifan Wu, Xin Zhang, Liang Chen CNS Neuroscience & Therapeutics.2024;[Epub] CrossRef
Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease David J. Rademacher Biomedicines.2023; 11(4): 1187. CrossRef
Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases Amir Gholamzad, Hadis Sadeghi, Maryam Azizabadi Farahani, Ali Faraji, Mahya Rostami, Sajad Khonche, Shirin Kamrani, Mahsa Khatibi, Omid Moeini, Seyed Armit Hosseini, Mohammadmatin Nourikhani, Mehrdad Gholamzad Neurology Letters.2023; 2(2): 55. CrossRef
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease? Z. Pirtošek, V. Leta, P. Jenner, M. Vérin Journal of Neural Transmission.2023; 130(11): 1395. CrossRef
Xeno-free generation of new Yazd human embryonic stem cell lines (Yazd4-7) as a prior stage toward good manufacturing practice of clinical-grade raw materials from discarded embryos: A lab resources report Fatemeh Hajizadeh-Tafti, Jalal Golzadeh, Fatemeh Akyash, Somayyeh-Sadat Tahajjodi, Ehsan Farashahi-Yazd, Hassan Heidarian-Meimandi, Behrouz Aflatoonian International Journal of Reproductive BioMedicine (IJRM).2023; 21(8): 619. CrossRef
Objective Stem cell treatment is a well-recognized experimental treatment among patients with Parkinson’s disease (PD), for which there are high expectations of a positive impact. Acupuncture with bee venom is one of the most popular complementary and alternative treatments for PD. Patient knowledge and attitudes towards these experimental treatments are unknown. Methods Using a 12-item questionnaire, a nationwide survey was conducted of 963 PD patients and 267 caregivers in 44 Korean Movement Disorders Society member hospitals from April 2013 to June 2013. The survey was performed by trained interviewers using conventional methods. Results Regarding questions on experimental treatments using stem cells or bee venom acupuncture, 5.1–17.7% of PD patients answered questions on safety, efficacy, and evidence-based practice incorrectly; however, more than half responded that they did not know the correct answer. Although safety and efficacy have not been established, 55.5% of PD patients responded that they were willing to receive stem cell treatment. With regard to participating in experimental treatments, there was a strong correlation between stem cell treatment and bee venom acupuncture (p < 0.0001, odds ratio = 5.226, 95% confidence interval 3.919–6.969). Younger age, higher education, and a longer duration of PD were all associated with a correct understanding of experimental treatments. Conclusions Our data suggest that relatively few PD patients correctly understand the safety and efficacy of experimental treatments and that PD patients are greatly interested in new treatments. We hope that our data will be used to educate or to plan educational programs for PD patients and caregivers.
Citations
Citations to this article as recorded by
Knowledge, Attitude, and Practice of Bee Venom Acupuncture Therapy on Rheumatoid Arthritis Among Patients in Saudi Arabia Shahd E Sharaf, Safaa Alsanosi, Abdullah R Alzahrani, Saeed S Al-Ghamdi, Sharaf E Sharaf, Nahla Ayoub International Journal of General Medicine.2022; Volume 15: 1171. CrossRef
Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease Patrick Bodilly Kane, Daniel M. Benjamin, Roger A. Barker, Anthony E. Lang, Todd Sherer, Jonathan Kimmelman Movement Disorders.2021; 36(1): 171. CrossRef
A Scoping Review of Patient and Public Perspectives on Cell and Gene Therapies Karen Macpherson, Olalekan Lee Aiyegbusi, Lauren Elston, Susan Myles, Jennifer Washington, Nisha Sungum, Mark Briggs, Philip Newsome, Melanie Calvert Regenerative Medicine.2021; 16(11): 1005. CrossRef
Patient and public perspectives on cell and gene therapies: a systematic review Olalekan Lee Aiyegbusi, Karen Macpherson, Lauren Elston, Susan Myles, Jennifer Washington, Nisha Sungum, Mark Briggs, Philip N. Newsome, Melanie J. Calvert Nature Communications.2020;[Epub] CrossRef
Knowledge, attitudes and perceptions of Parkinson's disease: A cross-sectional survey of Asian patients Onanong Jitkritsadakul, Nonglak Boonrod, Roongroj Bhidayasiri Journal of the Neurological Sciences.2017; 374: 69. CrossRef
Attitudes to Stem Cell Therapy Among Ischemic Stroke Survivors in the Lund Stroke Recovery Study Joseph Aked, Hossein Delavaran, Olle Lindvall, Bo Norrving, Zaal Kokaia, Arne Lindgren Stem Cells and Development.2017; 26(8): 566. CrossRef
Professional ethics in complementary and alternative medicines in management of Parkinson’s disease Hee Jin Kim, Beomseok Jeon, Sun Ju Chung Journal of Parkinson’s Disease.2016; 6(4): 675. CrossRef
Huntington’s disease (HD) is a genetic neurodegenerative disorder. The most common symptom of HD is abnormal involuntary writhing movements, called chorea. Antipsychotics and tetrabenazine are used to alleviate the signs and symptoms of HD. Stem cells have been investigated for use in neurodegenerative disorders to develop cell therapy strategies. Recent evidence indicates that the beneficial effects of stem cell therapies are actually mediated by secretory molecules, as well as cell replacement. Although stem cell studies show that cell transplantation provides cellular improvement around lesions in in vivo models, further work is required to elucidate some issues before the clinical application of stem cells. These issues include the precise mechanism of action, delivery method, toxicity and safety. With a focus on HD, this review summarizes cell therapy strategies and the paracrine effect of stem cells.
Citations
Citations to this article as recorded by
Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases Dongkyu Kim, Gun-Sik Cho, Choongseong Han, Dong-Hyuk Park, Hee-Kyung Park, Dong-Hun Woo, Jong-Hoon Kim Tissue Engineering and Regenerative Medicine.2017; 14(6): 653. CrossRef
Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy Ling Liu, Jin-Sha Huang, Chao Han, Guo-Xin Zhang, Xiao-Yun Xu, Yan Shen, Jie Li, Hai-Yang Jiang, Zhi-Cheng Lin, Nian Xiong, Tao Wang Molecular Neurobiology.2016; 53(10): 6698. CrossRef
Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes Ghanshyam Upadhyay, Sharmila Shankar, Rakesh K. Srivastava Molecular Neurobiology.2015; 52(1): 610. CrossRef
Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy Type 1 Induced Pluripotent Stem Cell-Derived Neural Stem Cells Guangbin Xia, Yuanzheng Gao, Shouguang Jin, S.H. Subramony, Naohiro Terada, Laura P.W. Ranum, Maurice S. Swanson, Tetsuo Ashizawa Stem Cells.2015; 33(6): 1829. CrossRef
Glycogen synthase kinase 3β inhibition enhanced proliferation, migration and functional re-endothelialization of endothelial progenitor cells in hypercholesterolemia microenvironment Bin Cui, Jun Jin, Xiaohan Ding, Mengyang Deng, Shiyong Yu, MingBao Song, Yang Yu, Xiaohui Zhao, Jianfei Chen, Lan Huang Experimental Biology and Medicine.2015; 240(12): 1752. CrossRef